Explore 3 Stock Ideas & Industry Insights Download Free Report

Cbd Life Sciences Inc

Healthcare US CBDL

0.0003USD
0.00(0%)

Last update at 2026-06-18T13:30:00Z

Day Range

0.00020.0003
LowHigh

52 Week Range

0.00010.001
LowHigh

Fundamentals

  • Previous Close 0.0003
  • Market Cap1.78M
  • Volume1290628
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.05188M
  • Revenue TTM0.18M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 0.08M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -0.04893M -0.75719M -0.07857M -0.85980M -
Minority interest - - - - -
Net income -0.04893M -0.75719M -0.07857M -0.85980M -
Selling general administrative - - 0.03M 0.17M -
Selling and marketing expenses - - 0.01M 0.35M -
Gross profit 0.04M -0.00989M -0.03060M -0.28026M -
Reconciled depreciation - - - - -
Ebit - -0.75719M -0.07857M -0.85980M -6.14120M
Ebitda -0.10170M -0.70163M -0.02302M -0.80625M -
Depreciation and amortization - 0.06M 0.06M 0.05M -
Non operating income net other - - - - -
Operating income -0.10170M -0.75719M -0.07857M -0.85980M -
Other operating expenses 0.20M 0.87M 0.25M 1.02M 0.02M
Interest expense - - - - 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 0.00000M 0.00000M -
Total revenue 0.10M 0.11M 0.17M 0.16M -
Total operating expenses 0.14M 0.75M 0.05M 0.58M -
Cost of revenue 0.06M 0.12M 0.20M 0.44M -
Total other income expense net 0.05M - -0.05747M -0.00000M -
Discontinued operations - - - - -
Net income from continuing ops - - - - -
Net income applicable to common shares - - - - -6.14120M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 0.81M 0.41M 0.42M 0.47M -
Intangible assets - 0.00951M 0.03M - -
Earning assets - - - - -
Other current assets - 0.20M 0.18M 0.17M -
Total liab 0.04M 0.01M 0.02M 0.17M -
Total stockholder equity 0.77M 0.39M 0.39M 0.47M -
Deferred long term liab - - - - -
Other current liab 0.00511M 0.01M 0.02M 0.17M -
Common stock 4.65M 4.37M 4.07M 4.07M 4.07M
Capital stock - - - - -
Retained earnings -15.36523M -15.31930M -14.56211M -14.48354M -13.62373M
Other liab - - - - 0.03M
Good will 0.10M 0.10M 0.10M 0.10M -
Other assets - - - - 0.00487M
Cash 0.33M 0.00655M 0.00252M 0.00056M -
Cash and equivalents - - - - -
Total current liabilities 0.04M 0.01M 0.02M 0.17M -
Current deferred revenue - - - - -
Net debt -0.33160M -0.00655M -0.00252M -0.00056M -
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 11.42M 11.28M 10.83M 14.89M -
Property plant equipment - - - - 0.19M
Total current assets 0.58M 0.24M 0.20M 0.18M 1.07M
Long term investments - - - - -
Net tangible assets - - - - 1.17M
Short term investments - - - - -
Net receivables 0.22M - - - -
Long term debt - - - - -
Inventory 0.04M 0.03M 0.02M 0.00812M 0.05M
Accounts payable 0.03M - - - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -0.01329M -4.07062M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00487M 0.00487M 0.00487M 0.00487M -
Deferred long term asset charges - - - - -
Non current assets total 0.22M 0.16M 0.22M 0.30M -
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - - -
Change to liabilities - - - - -0.01808M
Total cashflows from investing activities 0.05M - - -0.06900M -0.18581M
Net borrowings - - - - -
Total cash from financing activities 0.14M 0.59M 0.02M -0.15314M 7.49M
Change to operating activities - - - - -0.10850M
Net income -0.04893M -0.75719M -0.07857M -0.85980M -6.14120M
Change in cash 0.33M 0.00403M 0.00196M -1.02602M 1.02M
Begin period cash flow 0.00655M 0.00252M 0.00056M 1.03M -
End period cash flow 0.33M 0.00655M 0.00252M 0.00056M -
Total cash from operating activities -0.13915M -0.58308M -0.01664M -0.80418M -6.29318M
Issuance of capital stock - - - - -
Depreciation - 0.06M 0.06M 0.05M -
Other cashflows from investing activities 0.05M - - - -
Dividends paid - - - - -
Change to inventory -0.00327M -0.00448M -0.01643M 0.00207M -0.02540M
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities - - 0.02M -0.15314M -
Change to netincome - - - - -
Capital expenditures 0.00000M 0.00000M 0.00000M 0.07M 0.15M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.09022M 0.12M 0.00075M -0.15107M -
Stock based compensation - - - - -
Other non cash items - - 0.00562M 0.15M -
Free cash flow -0.13915M -0.58308M 0.00196M -1.02632M -

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CBDL
Cbd Life Sciences Inc
- -% 0.0003 - - 9.97 10.06 0.42 -0.6214
ZTS
Zoetis Inc
-2.82 3.58% 75.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR
-0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
- -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG
- -% 42.94 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

Profile

CBD Life Sciences Inc. engages in the development and marketing a line of cannabidiol based organic products. Its cannabidiol based organic products include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, coffee, wine, skincare line, tablets, and a line of pet products. CBD Life Sciences Inc. formerly known as Optium Cyber Systems, Inc. and Optium Cyber Systems, Inc. changed its name as CBD Life Sciences Inc. in January 2019. The company is based in Scottsdale, Arizona.

Cbd Life Sciences Inc

10953 N. Frank Lloyd Wright Boulevard, Scottsdale, AZ, United States, 85259

Key Executives

Name Title Year Born
Ms. Lisa Anne Nelson CEO, Pres, CFO, Sec., Treasurer & Director 1967
Mr. Matthew McGee Chief Marketing Officer 2000
Ms. Brianna Nelson Chief Product Developer & Director 1997
Ms. Lisa Anne Nelson CEO, President, CFO, Secretary, Treasurer & Director 1967
Mr. Matthew McGee Chief Marketing Officer 1999

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.